Where does AstraZeneca UK Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), AstraZeneca UK Limited ranks #12,815 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does AstraZeneca UK Limited hold?

AstraZeneca UK Limited holds 23 US utility patents granted between 2016 and 2024, spanning 8 technology areas.

What is AstraZeneca UK Limited's Innovation Score?

AstraZeneca UK Limited has an Innovation Score of 54.1 out of 100 (top 8% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is AstraZeneca UK Limited's patent grant rate increasing or decreasing?

AstraZeneca UK Limited's recent grant velocity is +260% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for AstraZeneca UK Limited's patents?

AstraZeneca UK Limited's patents average 24.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the AstraZeneca UK Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

AstraZeneca UK Limited

Q: What technology areas does AstraZeneca UK Limited focus on?

AstraZeneca UK Limited's top technology area is G16H (Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data) with 18 patents, ranking #267 of 3,149 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

USPTO PatentsView assignee record - 23 granted patents across 8 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: G16H (Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Astrazeneca ranks #12,815 of 49,997 tracked US assignees by granted-patent volume, with 23 patents across 8 technology areas.

#12,815
of 49,997 US assignees by volume: Top 8%
by Innovation Score (54.1/100): 24.1
avg claims per patent: +260%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R12815 · Foreign Corporation #12,815 · 23 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 23 grants
MID-PACK #12,815/49,997
PHOTO-FINISH Aquestive Therapeutics
CPC-NARROW G16H · 8 areas
INNOV-PAR 54.1/100
CLAIMS-DENSE 24.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +260% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Aquestive Therapeutics, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Astrazeneca’s 54.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.0 pts (20%) Velocity 18.7 pts (35%) Breadth 10.0 pts (18%) Claim depth 14.5 pts (27%)

Qualcomm Incorporated · highest

85
AstraZeneca UK · this assignee

54
3D Lighting… · lowest

7

What this shows Astrazeneca's Innovation Score is 54.1/100 (top 8% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Astrazeneca?

Each dot is one of Astrazeneca’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Astrazeneca’s own 24.1 claims/patent is ABOVE the 14.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Astrazeneca vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Astrazeneca's grants concentrate

AstraZeneca UK Limited is a focused PatentsView assignee: 8 CPC subclasses with 78.3% of grants classified under G16H (Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data). Peak complete grant year is 2023 (6 grants) versus a trough of 1 in 2016. By volume, Astrazeneca sits between Aquestive Therapeutics, Inc. and Automated Pet Care Products, LLC.

Astrazeneca's three-year grant acceleration

AstraZeneca UK Limited shows 14 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Aquestive Therape…

23
Armada Systems

23
Artsana USA

23
Aruze Gaming (Hon…

23
Atscale

23
Atea Pharmaceutic…

23
Aurora Office Equ…

23
Automated Pet Car…

23
Astrazeneca UK ◀

23

What this shows AstraZeneca holds 23 patents at rank #12,818, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near AstraZeneca

By rank, the assignees closest to #12,818 in granted patent volume.

Leaders in G16H (Healthcare Informatics)

Other assignees with the most granted patents in AstraZeneca's primary technology class.

Astrazeneca's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

54 Top 8% higher than 92% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

AstraZeneca UK Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	4.3%
2017	2	8.7%
2018	1	4.3%
2019	1	4.3%
2020	1	4.3%
2021	3	13.0%
2022	5	21.7%
2023	6	26.1%
2024	3	13.0%

Which technologies does AstraZeneca UK Limited patent most?

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 18

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 17

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 9

G06Q - Information AND Communication Technology [ICT] Specially Adapted FOR Administrative, Commercial, Financial, Managerial OR Supervisory PURPOSES; Systems OR Methods Specially Adapted FOR Administrative, Commercial, Financial, Managerial OR Supervisory Purposes, NOT Otherwise Provided FOR 5

G06F - Electric Digital Data Processing 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

C07D - Heterocyclic Compounds 1

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

AstraZeneca UK Limited's patent record in context - here's where to go next.

AstraZeneca UK Limited's lead technology class is G16H (Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data), 78.3% of its portfolio - see every assignee active in that class. Explore G16H
Ranked #12,815 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare AstraZeneca UK Limited against Aquestive Therapeutics, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 54.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.